Achaogen

Achaogen was a biotechnology company focused on developing antibiotics to fight serious bacterial infections, particularly those resistant to existing drugs. Their main product was plazomicin, an antibiotic designed to treat complicated urinary tract infections and bloodstream infections caused by resistant bacteria. Founded in 2003, Achaogen aimed to address the growing global health problem of antibiotic resistance. However, despite advances, the company faced challenges with regulatory approval and market competition, leading to financial difficulties. In 2019, Achaogen filed for bankruptcy and sold its assets, including its key drug, to focus on other areas of research.